Bile acid nuclear receptor FXR and digestive system diseases

Bile acids (BAs) are not only digestive surfactants but also important cell signaling molecules, which stimulate several signaling pathways to regulate some important biological processes. The bile-acid-activated nuclear receptor, farnesoid X receptor (FXR), plays a pivotal role in regulating bile acid, lipid and glucose homeostasis as well as in regulating the inflammatory responses, barrier function and prevention of bacterial translocation in the intestinal tract. As expected, FXR is involved in the pathophysiology of a wide range of diseases of gastrointestinal tract, including inflammatory bowel disease, colorectal cancer and type 2 diabetes. In this review, we discuss current knowledge of the roles of FXR in physiology of the digestive system and the related diseases. Better understanding of the roles of FXR in digestive system will accelerate the development of FXR ligands/modulators for the treatment of digestive system diseases.

• Publication year

  2015

• Venue

  Acta Pharmaceutica Sinica B

• Publication date

  2015-02-25

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.apsb.2015.01.004PMID 26579439PMCID 4629217
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

  2015cited by this paper
• Glucose sensing O‐GlcNAcylation pathway regulates the nuclear bile acid receptor farnesoid X receptor (FXR)

  2014cited by this paper
• Hepatic Farnesoid X-Receptor Isoforms α2 and α4 Differentially Modulate Bile Salt and Lipoprotein Metabolism in Mice

  2014cited by this paper
• Beyond intestinal soap—bile acids in metabolic control

  2014cited by this paper
• FXR silencing in human colon cancer by DNA methylation and KRAS signaling.

  2014cited by this paper
• FXR is a molecular target for the effects of vertical sleeve gastrectomy

  2014cited by this paper
• Genome-Wide Binding and Transcriptome Analysis of Human Farnesoid X Receptor in Primary Human Hepatocytes

  2014cited by this paper
• Activation of the nuclear receptor FXR enhances hepatocyte chemoprotection and liver tumor chemoresistance against genotoxic compounds.

  2013cited by this paper
• FXR signaling in the enterohepatic system.

  2013cited by this paper
• The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice.

  2013cited by this paper
• Obesity and diabetes.

  2013cited by this paper
• Mechanisms underlying weight loss after bariatric surgery

  2013cited by this paper
• Bile acid receptors in non-alcoholic fatty liver disease.

  2013cited by this paper
• A tea catechin, epigallocatechin-3-gallate, is a unique modulator of the farnesoid X receptor.

  2012cited by this paper
• Host-microbiota interactions in inflammatory bowel disease

  2012cited by this paper
• Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease

  2012cited by this paper
• Letter to the editor regarding the report of Duboc et al: connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel disease

  2012cited by this paper
• Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis

  2012cited by this paper
• Dysbiosis in the Pathogenesis of Pediatric Inflammatory Bowel Diseases

  2012cited by this paper
• Gut microbiota, epithelial function and derangements in obesity

  2012cited by this paper
• AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Mechanism of Tissue-Specific Farnesoid X Receptor in Suppressing the Expression of Genes in Bile-Acid Synthesis in Mice

  2012cited by this paper
• Promotion of liver regeneration/repair by farnesoid X receptor in both liver and intestine in mice

  2012cited by this paper
• Inflammatory bowel disease.

  2011cited by this paper
• Bile acids and colon cancer: Solving the puzzle with nuclear receptors.

  2011cited by this paper
• Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

  2011cited by this paper
• Sleeve gastrectomy in rats improves postprandial lipid clearance by reducing intestinal triglyceride secretion.

  2011cited by this paper
• Carcinogenicity of deoxycholate, a secondary bile acid

  2011cited by this paper
• FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway.

  2011cited by this paper
• FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis

  2011cited by this paper
• Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease.

  2011cited by this paper
• Farnesoid X receptor activation improves erectile dysfunction in models of metabolic syndrome and diabetes.

  2011cited by this paper
• FXR regulates liver repair after CCl4-induced toxic injury.

  2010cited by this paper
• FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats[S]

  2010cited by this paper
• The bile acid sensor FXR regulates insulin transcription and secretion.

  2010cited by this paper
• Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease.

  2010cited by this paper
• Sleeve gastrectomy induces loss of weight and fat mass in obese rats, but does not affect leptin sensitivity.

  2010cited by this paper
• Counter-regulatory role of bile acid activated receptors in immunity and inflammation.

  2010cited by this paper
• Bile acids: short and long term effects in the intestine

  2010cited by this paper
• Long-term effects of laparoscopic sleeve gastrectomy, gastric bypass, and adjustable gastric banding on type 2 diabetes

  2010cited by this paper
• Farnesoid X Receptor Deficiency in Mice Leads to Increased Intestinal Epithelial Cell Proliferation and Tumor Development

  2009cited by this paper
• The Bile Acid Receptor FXR Is a Modulator of Intestinal Innate Immunity1

  2009cited by this paper
• Improvement in Glucose Metabolism After Bariatric Surgery: Comparison of Laparoscopic Roux-en-Y Gastric Bypass and Laparoscopic Sleeve Gastrectomy: A Prospective Randomized Trial

  2009cited by this paper
• Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders.

  2009cited by this paper
• Diet, fecal water, and colon cancer--development of a biomarker.

  2009cited by this paper
• Bile acids: regulation of synthesis

  2009cited by this paper
• Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists.

  2009cited by this paper
• Role of bile acids and bile acid receptors in metabolic regulation.

  2009cited by this paper
• Marine n‐3 and saturated fatty acids in relation to risk of colorectal cancer in Singapore Chinese: A prospective study

  2009cited by this paper
• TGR5-mediated bile acid sensing controls glucose homeostasis.

  2009cited by this paper
• FXR an emerging therapeutic target for the treatment of atherosclerosis

  2009cited by this paper
• Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.

  2008cited by this paper
• Targeting bile-acid signalling for metabolic diseases

  2008cited by this paper
• Nuclear bile acid receptor FXR protects against intestinal tumorigenesis.

  2008cited by this paper
• Bariatric surgery: risks and rewards.

  2008cited by this paper
• Weight Loss, Appetite Suppression, and Changes in Fasting and Postprandial Ghrelin and Peptide-YY Levels After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy: A Prospective, Double Blind Study

  2008cited by this paper
• Bile acids and signal transduction: role in glucose homeostasis.

  2008cited by this paper
• Influence of sleeve gastrectomy on several experimental models of obesity: metabolic and hormonal implications.

  2008cited by this paper
• FXR signaling in metabolic disease

  2008cited by this paper
• Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes

  2008cited by this paper
• Targeting farnesoid X receptor for liver and metabolic disorders.

  2007cited by this paper
• Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.

  2007cited by this paper
• Nuclear receptors in human immune cells: expression and correlations.

  2007cited by this paper
• The cholesterol-raising factor from coffee beans, cafestol, as an agonist ligand for the farnesoid and pregnane X receptors.

  2007cited by this paper
• Regulation of hepatic Insig-2 by the farnesoid X receptor.

  2007cited by this paper
• Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice.

  2006cited by this paper
• The nuclear hormone receptor farnesoid X receptor (FXR) is activated by androsterone.

  2006cited by this paper
• FXR, a multipurpose nuclear receptor.

  2006cited by this paper
• FXR regulates organic solute transporters alpha and beta in the adrenal gland, kidney, and intestine.

  2006cited by this paper
• Mechanism of Growth Inhibition by Free Bile Acids in Lactobacilli and Bifidobacteria

  2006cited by this paper
• Farnesoid X receptor is essential for normal glucose homeostasis.

  2006cited by this paper
• A role for FXR and human FGF-19 in the repression of paraoxonase-1 gene expression by bile acids Published, JLR Papers in Press, November 3, 2005.

  2006cited by this paper
• Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor.

  2006cited by this paper
• FXR regulates organic solute transporters α and β in the adrenal gland, kidney, and intestine Published, JLR Papers in Press, October 26, 2005.

  2006cited by this paper
• Bile salt biotransformations by human intestinal bacteria Published, JLR Papers in Press, November 18, 2005.

  2006cited by this paper
• Identification of a hormonal basis for gallbladder filling

  2006cited by this paper
• The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice*

  2006cited by this paper
• Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis

  2006cited by this paper
• Bile acids as carcinogens in human gastrointestinal cancers.

  2005cited by this paper
• Regulation of carbohydrate metabolism by the farnesoid X receptor.

  2005cited by this paper
• Diet, anaerobic bacterial metabolism, and colon cancer: a review of the literature.

  2005cited by this paper
• Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis.

  2005cited by this paper
• Transient impairment of the adaptive response to fasting in FXR‐deficient mice

  2005cited by this paper
• The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter.

  2005cited by this paper
• Bile Acids Decrease Hepatic Paraoxonase 1 Expression and Plasma High-Density Lipoprotein Levels Via FXR-Mediated Signaling of FGFR4

  2005cited by this paper
• Role of FXR in regulating bile acid homeostasis and relevance for human diseases.

  2005cited by this paper
• The Heteromeric Organic Solute Transporter α-β, Ostα-Ostβ, Is an Ileal Basolateral Bile Acid Transporter*

  2005cited by this paper
• Fos/AP‐1 proteins in bone and the immune system

  2005cited by this paper
• Farnesoid X receptor: from structure to potential clinical applications.

  2005cited by this paper
• Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c.

  2004cited by this paper
• The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis.

  2004cited by this paper
• Bile Acids Regulate Gluconeogenic Gene Expression via Small Heterodimer Partner-mediated Repression of Hepatocyte Nuclear Factor 4 and Foxo1*

  2004cited by this paper
• The Farnesoid X Receptor (FXR) as Modulator of Bile Acid Metabolism

  2004cited by this paper
• The Bile Acid Nuclear Receptor FXR and the Bile Acid Binding Protein IBABP Are Differently Expressed in Colon Cancer

  2004cited by this paper
• Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5.

  2004cited by this paper
• Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) regulates triglyceride metabolism by activation of the nuclear receptor FXR

  2004cited by this paper
• Prevention of cholesterol gallstone disease by FXR agonists in a mouse model

  2004cited by this paper
• Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR.

  2004cited by this paper
• Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats

  2003cited by this paper
• The Farnesoid X-receptor Is an Essential Regulator of Cholesterol Homeostasis*

  2003cited by this paper
• Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis.

  2003cited by this paper

• Bidirectional causal relationship between 91 blood cells and endometriosis at different sites: A Mendelian randomization study

  2026cites this paper
• Deciphering the diet-inflammatory bowel disease relationship: knowledge gaps and future perspectives.

  2026cites this paper
• Targeting the intestinal barrier with traditional Chinese medicine for non-alcoholic fatty liver disease: mechanistic insights and therapeutic perspectives

  2026cites this paper
• First-trimester preeclampsia prediction model via integrative machine learning of maternal risk profiles and laboratory markers

  2026cites this paper
• Bile acid signaling, metabolism, and aging

  2026cites this paper
• Multi-omics elucidates the role of dietary Clostridium butyricum in modulating gut health of Pelophylax nigromaculatus

  2026cites this paper
• Exploring the mechanism of Jianpi Guchang Recipe and Its Compound: Inhibition Liver Metastasis in Colorectal Carcinoma through regulation of the Bile Acid-FXR-FGF19 Axis.

  2026cites this paper
• Capsaicin Improves Lipid Metabolism Disorders Caused by LPS-Induced Immune Stress in Weaned Piglets.

  2026cites this paper
• Xiayuxue decoction alleviates MASH by regulating gut microbiota, bile acid metabolism, and m6A modification.

  2026cites this paper
• Serum total bile acids are associated with coronary artery calcification as assessed by non gated chest computed tomography: a multicenter study

  2026cites this paper
• Cordyceps cicadae polysaccharides ameliorate ulcerative colitis by modulating the gut microbiota and regulating the bile acid/FXR/NF-κB signaling pathway.

  2026cites this paper
• Schisantherin A: Remodeling Gut Microbiota to Activate the Gut–Immune–Neural–Adipose Axis for Thermogenesis

  2026cites this paper
• Liver–pancreas communication in disease and drug development

  2026cites this paper
• Bile acids as gatekeepers: Orchestrating gut-liver axis for metabolic and immune balance.

  2026cites this paper
• Organ cross-talk: molecular mechanisms, biological functions, and therapeutic interventions for diseases

  2026cites this paper
• Taurocholate mitigates LPS-induced intestinal barrier injury via host-microbiota and inflammatory pathway regulation.

  2026cites this paper
• Gut microbiota, a new approach to management of polycystic ovary syndrome: a systematic review, meta-analysis and meta-evidence of 26 randomized controlled trials.

  2026cites this paper
• Epigenetic regulation and posttranslational modifications of FXR: underlying mechanisms and implications in digestive diseases.

  2026cites this paper
• Bifidobacterium's Influential Role in the Battle Against Obesity: Going Beyond Probiotics.

  2025cites this paper
• Nuclear receptors in health and disease: signaling pathways, biological functions and pharmaceutical interventions

  2025cites this paper
• Faecalibacterium prausnitzii Ameliorates DSS-Induced Colitis via Modulating Bile Acid Metabolism and Regulating FXR Signaling

  2025cites this paper
• Clostridium butyricum protects the ileal barrier in mice by regulating the farnesoid X receptor signaling pathway.

  2025cites this paper
• Fatty acid-binding proteins in cancers

  2025cites this paper
• GOS-Modulated Gut Microbiota in Mice Ameliorates Obesity in High-Fat Diet-Fed Mice Through the Gut-Liver Axis and Bile Acid Pathway.

  2025cites this paper
• Yinchenhao Decoction Mitigates Cholestatic Liver Injury in Mice via Gut Microbiota Regulation and Activation of FXR-FGF15 Pathway

  2025cites this paper
• Advances of exosome regulating-FXR to repair inflammatory bowel disease (Review)

  2025cites this paper
• Farnesoid X Receptor Alleviates Cisplatin‐Induced Kidney Inflammatory Injury by Inhibiting Tlr4/NF‐κB Pathway

  2025cites this paper
• Low molecular weight Astragalus membranaceus polysaccharides alleviates dextran sulfate sodium-induced colitis in mice.

  2025cites this paper
• Determinants of site-selectivity in human ileal bile acid-binding protein by NMR dynamic analysis of a functionally-impaired mutant.

  2025cites this paper
• Targeting Bile-Acid Metabolism: Nutritional and Microbial Approaches to Alleviate Ulcerative Colitis

  2025cites this paper
• Role of mitogens in normal and pathological liver regeneration

  2025cites this paper
• Probiotics for the treatment of hyperlipidemia: Focus on gut-liver axis and lipid metabolism.

  2025cites this paper
• Nanobilosome as custom-tailored modality in addressing Alzheimer’s disease: advancements and translational glitches

  2025cites this paper
• Hepatoprotective Effects of Cilnidipine in Cholestatic Liver Disease: Role of FXR and NRF2 Signalling

  2025cites this paper
• Geniposidic Acid Targeting FXR “S332 and H447” Mediated Conformational Change to Upregulate CYPs and miR‐19a‐3p to Ameliorate Drug‐Induced Liver Injury

  2025cites this paper
• Oligosaccharides and small molecule components of Sijunzi decoction modulate the gut microbiota-bile acid axis to synergistically alleviate spleen deficiency syndrome.

  2025cites this paper
• Toxic effects of emerging pollutants on mucosal organs of teleost fish: A review focusing on mucosal microbiota, physical barrier and immune barrier.

  2025cites this paper
• Gut microbiota at the crossroads of food additives, pollutants, and chronic disease risk

  2025cites this paper
• Double-negative T cells in combination with ursodeoxycholic acid ameliorates immune-mediated cholangitis in mice

  2025cites this paper
• Gut Microbiota in the Regulation of Intestinal Drug Transporters: Molecular Mechanisms and Pharmacokinetic Implications

  2025cites this paper
• Emodin and physcion alleviate cholestatic liver injury by targeting FXR: hepatoprotective components identified in processed Polygonum multiflorum Thunb. using a comprehensive two-dimensional biochromatography system

  2025cites this paper
• Lithocholic Acid Species: Metabolism, Signaling Pathways, and Clinical Significance in Enterohepatic Diseases

  2025cites this paper
• Gut Microbiota and Its Metabolite Taurine-β-Muricholic Acid Contribute to Antimony- and/or Copper-Induced Liver Inflammation

  2025cites this paper
• Bile acid receptor FXR promotes intestinal epithelial ferroptosis and subsequent ILC3 dysfunction in neonatal necrotizing enterocolitis.

  2025cites this paper
• Antibiotic-induced gut dysbiosis: unraveling the gut-heart axis and its impact on cardiovascular health

  2025cites this paper
• Gut microbiota-derived UDCA enhanced by metformin inhibits FXR to activate autophagy against MCD diet-induced NAFLD in mice.

  2025cites this paper
• From pathogenic mechanisms to therapeutic perspectives: a review of gut microbiota and intestinal mucosal immunity in inflammatory bowel disease

  2025cites this paper
• Impact of Periodontal Host-Modulation Therapies on Oral–Gut Microbiome Axis in Periodontitis Patients with Hematological Diseases: A Narrative Review

  2025cites this paper
• Serum FGF19 combined with GGT and other biomarkers predicted native liver survival following Kasai portoenterostomy in early biliary atresia

  2025cites this paper
• Hepatic and intestinal tissue-specific Fxr deficiency alters bile acid homeostasis in female mice.

  2025cites this paper
• GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications

  2025cites this paper
• Therapeutic Potential of Polyphenols in Targeting Th17/Treg Balance for Intestinal Barrier Maintenance

  2025cites this paper
• Differential Roles of Individual Bile Acid in Physiology and Disease.

  2025cites this paper
• From Nuclear Receptor Regulation to Spleen Activating and Accumulation Resolving Therapy: A Review of Traditional Chinese Medicine Against Diabetes and Inflammation

  2025cites this paper
• Short-Chain Fatty Acids as a Therapeutic Strategy in Parkinson’s Disease: Implications for Neurodegeneration

  2025cites this paper
• Ferulic acid improved lipid metabolism of blunt snout bream, Megalobrama amblycephala juveniles via the intestinal microbiota and metabolites

  2025cites this paper
• From dysbiosis to precision therapy: decoding the gut-bladder axis in bladder carcinogenesis

  2025cites this paper
• Chenodeoxycholic acid triggers gastric mucosal injury by inducing apoptosis and FXR activation

  2025cites this paper
• Poria cocos polysaccharides as a carbon source promotes the proliferation of Parabacteroides distasonis to ameliorate ulcerative colitis: A mechanistic study based on the secondary bile acid-TGR5 axis

  2025cites this paper
• Lipidomics, Microbiota, and Intestinal Clostridioides difficile Infection Outcome

  2025cites this paper
• The role of brain–liver–gut Axis in neurological disorders

  2025cites this paper
• FXR-ApoC2 pathway activates UCP1-mediated thermogenesis by promoting the browning of white adipose tissues

  2025cites this paper
• Diets for inflammatory bowel disease: impact on microbiome and immunomodulatory microbial metabolites

  2025cites this paper
• Celastrol ameliorates metabolic dysfunction associated steatohepatitis by regulating the CYP7B1-mediated alternative bile acid synthetic pathway.

  2025cites this paper
• Role of gut microbiota in the pathogenesis of metabolic syndrome: an updated comprehensive review from mechanisms to clinical implications

  2025cites this paper
• Citrus Pectin Supplementation Alleviated Hepatic Lipid Accumulation through Gut Microbiota Indole Lactic Acid Promoting Hepatic Bile Acid Synthesis and Excretion

  2025cites this paper
• Oat Avenanthramide‐C Alleviates DSS‐Induced Colitis Through Regulating Intestinal Immune Activity and Gut Microbiota in Mice

  2025cites this paper
• The effect of pre/pro/synbiotics on cardiometabolic health in patients with polycystic ovary syndrome: A systematic review, meta-analysis and meta-evidence

  2025cites this paper
• Shen-Bai-Jie-Du decoction inhibits colorectal tumorigenesis by attenuating the malignancy of cancer stem cells via the gut microbiota-bile acid-FXR axis.

  2025cites this paper
• Water-soluble Poria cocos polysaccharide improves alcoholic liver disease via modulation of gut microbiota-mediated intestinal bile acids-farnesoid X receptor.

  2025cites this paper
• Functional regulation of cytotoxic T cells by gut microbial metabolites.

  2025cites this paper
• Crippled Hepatocarcinogenesis Inhibition of Quercetin in Glycolysis Pathway with Hepatic Farnesoid X Receptor Deficiency.

  2025cites this paper
• Maternal Western Diet Programmes Bile Acid Dysregulation and Hepatic Fibrosis in Fetal and Juvenile Macaques

  2025cites this paper
• Exploring Key Lipid Molecules of Primary Dysmenorrhea for Elucidating the Biological Effects of Danggui Shaoyao San Using UPLC-Q-TOF-MS-Based Lipidomics.

  2025cites this paper
• Effect of laparoscopic cholecystectomy on plasma levels of EETs, arachidonic acids derived lipid mediators.

  2025cites this paper
• Schisantherin A interacts with gut bacteria to stimulate adipose tissue thermogenesis in obese mice via a TGR5‒p-CREB‒STAT6 signaling pathway

  2025cites this paper
• Blood Exposure Profile of Per- and Polyfluoroalkyl Substances and Their Alternatives in Pregnant Women: Pathophysiological Concentrations, Interactions with Endogenous Biomolecules, and Associated Potential Health Risks.

  2025cites this paper
• Specific Formulation of Xylo-Oligosaccharides and Isomalto-Oligosaccharides Alleviates Metabolic Disturbance and Intestinal Barrier Dysfunction Induced by High-Fat Diet.

  2025cites this paper
• Protective Effect of Pediococcus pentosaceus Li05 on Constipation via TGR5/TPH1/5‐HT Activation

  2025cites this paper
• Strategies to inhibit steroid cytochrome P450 enzymes to benefit human health: development of steroid ligands for P450s 17A1, 19A1, and 8B1 to treat cancer and obesity.

  2025cites this paper
• Cortex Dictamni induces cholestatic liver injury via the bile acid-gut-liver axis mediated by FXR signaling pathway in rats.

  2025cites this paper
• Multi-omics analysis reveals the associations between altered gut microbiota, metabolites, and cytokines during pregnancy

  2024cites this paper
• FXR controls duodenogastric reflux-induced gastric inflammation through negatively regulating ER stress-associated TNXIP/NLPR3 inflammasome

  2024cites this paper
• Replacement of fish meal with full fat Hermetia illucens modulates hepatic FXR signaling in juvenile rainbow trout (Oncorhynchus mykiss): Exploring a potential role of ecdysteroids

  2024cites this paper
• Bile salt signaling and bile salt-based therapies in cardiometabolic disease

  2024influential citation
• Hepatic Zbtb18 (Zinc Finger and BTB Domain Containing 18) alleviates hepatic steatohepatitis via FXR (Farnesoid X Receptor)

  2024cites this paper
• Gut microbiota-derived metabolites as novel therapies for inflammatory bowel diseases: Role of nuclear receptors

  2024cites this paper
• Noninvasive biomarkers implicated in urea and TCA cycles for metabolic liver disease

  2024cites this paper
• FXR promotes clear cell renal cell carcinoma carcinogenesis via MMP-7-regulated EMT pathway

  2024cites this paper
• Taurohyocholic acid acts as a potential predictor of the efficacy of tyrosine kinase inhibitors combined with programmed cell death-1 inhibitors in hepatocellular carcinoma

  2024cites this paper
• 电离辐射对肠道胆汁酸代谢的影响：甘氨熊脱氧胆酸辐射防护作用机制的探索

  2024cites this paper
• Bile’s Hidden Weapon: Modulating the Microbiome and Tumor Microenvironment

  2024cites this paper
• Design, synthesis and FXR partial agonistic activity of anthranilic acid derivatives bearing aryloxy moiety as therapeutic agents for metabolic dysfunction-associated steatohepatitis.

  2024cites this paper
• Gestational diabetes mellitus aggravates adverse perinatal outcomes in women with intrahepatic cholestasis of pregnancy

  2024cites this paper
• Biological functions and pharmacological behaviors of bile acids in metabolic diseases

  2024cites this paper
• Flavonoids, gut microbiota and cardiovascular disease: Dynamics and interplay.

  2024cites this paper
• Polysaccharide of Dicliptera chinensis (L.) Juss. alleviated cholestatic liver disease by modulating the FXR pathway.

  2024cites this paper
• Simulations Reveal Unique Roles for the FXR Hinge in the FXR–RXR Nuclear Receptor Heterodimer

  2024cites this paper
• Cross-talk between macrophages and gut microbiota in inflammatory bowel disease: a dynamic interplay influencing pathogenesis and therapy

  2024cites this paper
• The Impact of Gastrectomy on Inflammatory Bowel Disease Risk in Gastric Cancer Patients: A Critical Analysis

  2024cites this paper